[4-(hexahydro-pyrrolo[3,4-c]pyrrol-2-yl )-6-trifluoromethylpyrimidin-2-yl] dimethyl-amine | 1293284-91-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: [4-(hexahydro-pyrrolo[3,4-c]pyrrol-2-yl )-6-trifluoromethylpyrimidin-2-yl] dimethyl-amine
• 英文别名: [4-(Hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-dimethyl-amine；4-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl)-N,N-dimethyl-6-(trifluoromethyl)pyrimidin-2-amine
• CAS: 1293284-91-9
• 化学式: C₁₃H₁₈F₃N₅
• 分子量: 301.315
• InChiKey: LSDALQSCQSTZOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  44.3
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  [4-(hexahydro-pyrrolo[3,4-c]pyrrol-2-yl )-6-trifluoromethylpyrimidin-2-yl] dimethyl-amine 、 5-fluoro-2-(pyrimidin-2-yl)benzoic acid 生成 4-{5-[(5-fluoro-2-pyrimidin-2-ylphenyl)carbonyl]hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-N,N-dimethyl-6-(trifluoromethyl)pyrimidin-2-amine
  参考文献：
  名称：

  Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

  摘要：

  本文描述了二取代的八氢吡咯[3,4-c]吡咯化合物，可用作促进荷尔蒙受体的调节剂。这种化合物可能在药物组合物和治疗由荷尔蒙活动介导的疾病状态、障碍和条件，例如失眠症的方法中有用。

  公开号：

  US08653263B2

文献信息

• [EN] DISUBSTITUTED OCTAHY-DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS<br/>[FR] OCTAHYDROPYRROLO [3,4-C] PYRROLES DISUBSTITUÉS UTILISÉS COMME MODULATEURS DU RÉCEPTEUR DE L'OREXINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2012145581A1

  公开（公告）日：2012-10-26

  Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  描述了二取代的八氢吡咯[3,4-c]吡咯化合物，这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和病况的方法中有用，比如失眠。
• [EN] DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS<br/>[FR] OCTAHYDROPYRROLO[3,4-C]PYRROLES DISUBSTITUÉS EN TANT QUE MODULATEURS DE RÉCEPTEUR D'OREXINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011050198A1

  公开（公告）日：2011-04-28

  Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  描述了二取代的八氢吡咯并[3,4-c]吡咯化合物，这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和症状的方法中有用，比如失眠。
• DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS
  申请人：Chai Wenying

  公开号：US20120208812A1

  公开（公告）日：2012-08-16

  Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  本文描述了双取代的八氢吡咯并[3,4-c]吡咯化合物，这些化合物可用作促进睡眠荷尔蒙受体的调节剂。这些化合物可以用于药物组成物和治疗疾病状态、疾病和条件的方法，这些疾病状态、疾病和条件是由促进睡眠荷尔蒙活性介导的，例如失眠。
• DISUBSTITUTED OCTAHYDROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS
  申请人：Letavic Michael A.

  公开号：US20140171430A1

  公开（公告）日：2014-06-19

  Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  本文介绍了双取代的八氢吡咯并[3,4-c]吡咯化合物，其可用作促进荷尔蒙受体的调节剂。这些化合物可以用于制备药物组合物，并用于治疗由荷尔蒙活性介导的疾病状态、紊乱和情况，如失眠等。
• Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US11059828B2

  公开（公告）日：2021-07-13

  Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  本文描述了二取代的八氢吡咯并[3,4-c]吡咯化合物，它们可用作奥曲肽受体调节剂。此类化合物可用于治疗由奥曲肽活性介导的疾病状态、失调和病症（如失眠）的药物组合物和方法中。